Relapse of Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria and Ketonuria Associated With Pre-operative Sodium-Glucose Co-transporters 2 (SGLT-2) Inhibitor Use
Abstract
Sodium-glucose co-transporters 2 (SGLT2) inhibitors are an important class of medications that have become increasingly used not only in the management of type 2 diabetes but also for cardioprotection and slowing the progression of renal dysfunction. However, clinicians should be aware of the risk of euglycemic diabetic ketoacidosis associated with their use, particularly in cases of severe illness, volume depletion, decreased carbohydrate intake, or recent surgery. We present a case of a 68-year-old male, whose type 2 diabetes mellitus was controlled with dapagliflozin 10 mg daily, and was electively admitted for left tibial fracture surgery. He continued to take dapagliflozin until one day prior to the scheduled surgery date and was discharged home the day after the procedure. Twelve hours after discharge, he presented again to the emergency room with severe euglycemic diabetic ketoacidosis (EuDKA) and acute kidney injury (AKI), which required intensive care admission and initiation of the diabetic ketoacidosis (DKA) protocol. Despite successful treatment of EuDKA and AKI, and subsequent transfer to the medical floor, his urinalysis showed persistent ketonuria and glucosuria, even though blood sugar readings remained below the renal threshold of glucosuria. On the medical floor, euglycemic diabetic ketoacidosis recurred eight days after the last dose of dapagliflozin. The second EuDKA episode resolved following another 24 hours of treatment with the DKA protocol. The…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.